Premium
Unraveling the Role of Arg4 and Arg6 in the Auto‐Inhibition Mechanism of GSK 3 β From Molecular Dynamics Simulation
Author(s) -
Mou Linkai,
Li Molin,
Lu ShaoYong,
Li Shuai,
Shen Qiancheng,
Zhang Jian,
Li Chuangang,
Lu Xuefeng
Publication year - 2014
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12286
Subject(s) - gsk 3 , wnt signaling pathway , phosphorylation , molecular dynamics , glycogen synthase , serine , chemistry , kinase , protein kinase b , mutant , threonine , signal transduction , gsk3b , biochemistry , wild type , biology , biophysics , computational chemistry , gene
Glycogen synthase kinase 3 β ( GSK 3 β ) is a multifunctional serine/threonine protein kinase that is involved in several biological processes including insulin and Wnt signaling pathways. GSK 3 β can be phosphorylated by the protein kinase B ( PKB ). The mutations of A rg4 and A rg6 to alanine at N ‐terminal GSK 3 β have been reported to impair its ability to autophosphorylate at S er9. Despite the extensive experimental observations, the detailed mechanism for the auto‐inhibition of GSK 3 β has not been rationalized at the molecular level. In this study, we have demonstrated the structural consequences of GSK 3 β R 4 A and R 6 A mutations and the atomic changes that influenced the loss of PKB ‐binding affinity. Molecular dynamics simulation results suggested significant loss in atomic contacts in the R 4 A and R 6 A mutant systems compared to the wild‐type system. Furthermore, we observed many notable changes (such as conformation, residues motions, hydrogen bonds, and binding free energy) in the mutated GSK 3 β – PKB complexes. Loss of binding affinity in the mutated systems rendered the decrease in GSK 3 β phosphorylation, which, in turn, impaired the auto‐inhibition of GSK 3 β . The significant outcomes obtained from this study can explain the auto‐inhibition of GSK 3 β and maybe facilitate type 2 diabetes mellitus researches and in developing the potent drug therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom